For example, in clinical trials of semaglutide 2.4 mg (Wegovy), nausea occurred in approximately 44% of patients, while rates for tirzepatide and other GLP-1s vary: Nausea : Often described as mild queasiness, particularly after eating, though some patients experience more pronounced nausea Bloating and abdominal fullness : A sensation of delayed digestion or food sitting heavily in the stomach Changes in bowel habits : Constipation affects approximately 15-30% of patients (varying by medication and dose), while some experience diarrhea or alternating patterns [1] [4] Decreased appetite : Beyond simple fullness, many report a fundamental shift in food thoughts, with reduced cravings and less mental preoccupation with eating Some patients report fatigue or low energy , particularly during the initial weeks
Median nerve compression test direct pressure over the carpal tunnel reproduces symptoms
Users describe hunger that feels almost painful, not just increased appetite but genuine distress if food is not available
As more GLP-1 options enter the market with different payer coverage rules, the administrative burden on your teams grows
Digital-based DSMES can support people to live well with diabetes [107], showing promising and often comparable outcomes to face-to-face programmes [108,109]
